Back to results
US 2014/0271820 A1Published application
Liposome oxaliplatin compositions for cancer therapy
AssigneeMallinckrodt Inc.
InventorWilliam McGhee
Life of this patent
Estimating the term…
Abstract
The present invention provides a composition for the treatment of cancer including zwitterionic liposomes consisting essentially of: 50-70 mol % of a phosphatidylcholine lipid, 25-45 mol % of cholesterol, and 2-8 mol % of a PEG-lipid; and oxaliplatin. Oxaliplatin is encapsulated in the liposomes in an amount such that the ratio of the total lipid weight to the oxaliplatin weight is from about 20:1 to about 65:1. Methods for the preparation of liposomal oxaliplatin and the treatment of cancer are also disclosed.
Claims25
A composition for the treatment of cancer, comprising:
- (a) zwitterionic liposomes consisting essentially of from about 50 mol % to about 70 mol % of a phosphatidylcholine lipid or mixture of phosphatidylcholine lipids, from about 25 mol % to about 45 mol % of cholesterol, and from about 2 mol % to about 8 mol % of a PEG-lipid;
- and
- (b) oxaliplatin, encapsulated in said liposome in an amount such that the ratio of the total lipid weight to the oxaliplatin weight is from about 20:1 to about 65:1;
- wherein said phosphatidylcholine lipid or mixture of phosphatidylcholine lipids have fatty acid chains of 14 carbon atoms or more, and no more than one of the two fatty acid chains is unsaturated.
1 more element
Dependencies are inferred from the claim text.